Candel Therapeutics (CADL) Change in Accured Expenses (2020 - 2025)

Candel Therapeutics' Change in Accured Expenses history runs 6 years deep, the most recent figure standing at $2.3 million for Q4 2025.

• In Q4 2025, Change in Accured Expenses rose 320.77% year-over-year to $2.3 million; the TTM figure through Dec 2025 stood at $2.3 million (up 197.75% YoY), while the FY2025 annual figure was $2.3 million, up 197.75% from the prior year.
• Change in Accured Expenses came in at $2.3 million for Q4 2025 at Candel Therapeutics, up from $1.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.3 million in Q4 2025 to a low of -$2.4 million in Q1 2025.
• A 5-year average of $213600.0 and a median of $493500.0 in 2024 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses sank 2088.89% in 2023 and surged 1692.94% in 2024, its largest moves.
• Candel Therapeutics' Change in Accured Expenses stood at $719000.0 in 2021, then sank by 39.5% to $435000.0 in 2022, then soared by 117.47% to $946000.0 in 2023, then plunged by 42.49% to $544000.0 in 2024, then jumped by 320.77% to $2.3 million in 2025.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $2.3 million, $1.2 million, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison